Článek pojednává o roli ARTA preparátů zejména v terapii metastatického kastračně rezistentního karcinomu, uvádí dostupná data a jejich využití v praktickém rozhodování v léčbě.

The article deals with the role of ARTAs, particularly in treating metastatic castration-resistant prostate cancer, presenting available data and their utilization in practical treatment-related decision making.

• MeSH
• Abiraterone Acetate pharmacology   therapeutic use   MeSH
• Androgen Antagonists pharmacology   therapeutic use   MeSH
• Docetaxel pharmacology   therapeutic use   MeSH
• Phenylthiohydantoin pharmacology   MeSH
• Cytochrome P-450 Enzyme Inhibitors pharmacology   MeSH
• Humans MeSH
• Prostatic Neoplasms, Castration-Resistant * drug therapy   classification   pathology   MeSH
• Radiotherapy methods   MeSH
• Neoplasm Grading MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Publication type
• Review MeSH

• MeSH
• Survival Analysis MeSH
• CTLA-4 Antigen antagonists & inhibitors   MeSH
• Programmed Cell Death 1 Receptor antagonists & inhibitors   MeSH
• Everolimus therapeutic use   MeSH
• Carcinoma, Transitional Cell drug therapy   MeSH
• Carcinoma, Renal Cell drug therapy   pathology   MeSH
• Humans MeSH
• Urinary Bladder Neoplasms drug therapy   pathology   MeSH
• Prostatic Neoplasms, Castration-Resistant drug therapy   classification   MeSH
• Prognosis MeSH
• Seminoma pathology   therapy   MeSH
• Semen Preservation MeSH
• Check Tag
• Humans MeSH
• Male MeSH